CTOs on the Move

Cybertech Medical

www.cybertechmedical.com

 
Cybertech Medical is a La Verne, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

BabelBark

BabelBark is the most comprehensive pet health management tool available, managing pets care, records and fitness all in one place. The BabelBark mobile app for pet parents links with the software platforms for pet businesses, shelters and veterinarians to help pets live the happiest, healthiest lives possible—by connecting everyone who cares for them! Whether you love, treat, groom, train, walk or sit for pets—BabelBark helps you do it even better.

Phibro Animal Health

Phibro Animal Health Corporation is a global leader in the fields of animal health and performance products, with thousands of customers worldwide and a global workforce of 900 hardworking employees.

Pike Market Child Care

Pike Market Child Care is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Morristown Manor

Morristown Manor is a Morristown, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PanOptica

At PanOptica, our aim is to develop new ocular therapies that help patients see their very best throughout their lives. Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient`s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.